Cervical cytology screening

Obstetrics and Gynecology

Volumn 114, Issue 6, 2009, Pages 1409-1420

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

CANCER SCREENING; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; FALSE NEGATIVE RESULT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NOMENCLATURE; NONHUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLING ERROR; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; AGE; ARTICLE; CYTOLOGY; FEMALE; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; STANDARD; UTERINE CERVIX TUMOR; VAGINA SMEAR;

AGE FACTORS; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; SPECIMEN HANDLING; TERMINOLOGY AS TOPIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 73449130155     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181c6f8a4     Document Type: Review

References (97)

1. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al, editors. SEER cancer statistics review, 1975-2006. Bethesda (MD): National Cancer Institute; 2009. Available at: http://seer.cancer.gov/ csr/1975-2006. Retrieved August 25, 2009. (Level II-3)
2. American Cancer Society. Cancer facts and figures 2009. Atlanta (GA): ACS; 2009. Available at: http://www.cancer. org/downloads/STT/500809web.pdf. Retrieved July 20, 2009. (Level II-3)
3. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24(suppl 3):S3/11-25. (Level III)
4. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996;(21):1-6. (Level III)
5. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113:214-226 (Level III)
6. van der Graaf Y, Klinkhamer PJ, Vooijs GP. Effect of population screening for cancer of the uterine cervix in Nijmegen, The Netherlands. Prev Med 1986;15:582-590 (Level II-3)
7. National Institutes of Health. Cervical cancer. NIH Consensus Statement 1996;14(1):1-38. Available at: http://consensus.nih.gov/1996/ 1996CervicalCancer102P DF.pdf. Retrieved July 20, 2009. (Level III)
8. Health care for undocumented immigrants. ACOG Committee Opinion No. 425. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113: 251-254 (Level III)
9. Shingleton HM, Patrick RL, Johnston WW, Smith RA. The current status of the Papanicolaou smear. CA Cancer J Clin 1995;45:305-320 (Level III)
10. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111:145-153 (Level III)
11. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. JAMA 2001;285:1500-1505 (Level II-3)
12. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(suppl 3):S3/42-51. (Level III)
13. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265 (Level III) (Pubitemid 34293391)
14. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Level II-2)
15. Kiviat N. Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 1996;175:1099-1104 (Level III)
16. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428 (Level II-2)
17. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132: 277-284 (Level II-2)
18. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillo-mavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836 (Level II-2)
19. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papil-lomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-192 (Level II-3)
20. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students [published erratum appears in Am J Epidemiol 2003;157:858]. Am J Epidemiol 2003;157:218-226 (Level II-2)
21. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738 (Level II-3)
22. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-715 (Level III)
23. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. N Engl J Med 2003;348:518-527 (Meta-analysis) (Pubitemid 36159887)
24. Park J, Sun D, Genest DR, Trivijitsilp P, Suh I, Crum CP. Coexistence of low and high grade squamous intraepithe-lial lesions of the cervix: morphologic progression or multiple papillomaviruses? Gynecol Oncol 1998;70:386-391 (Level II-3)
25. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-819 (Level II-3)
26. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84: 1616-1623 (Level II-3)
27. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757 (Level II-3)
28. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009;113:595-600. (Level III)
29. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678-1683 (Level II-2)
30. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007; 197:141.e1-141.e6. (Level II-2)
31. Fuchs K, Weitzen S, Wu L, Phipps MG, Boardman LA. Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J Pediatr Adolesc Gynecol 2007;20:269-274 (Level II-3)
32. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. N Engl J Med 2007; 356:1928-1943. (Level I)
33. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. FUTURE II Study Group. N Engl J Med 2007;356:1915-1927 (Level I)
34. Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine 2006;24(suppl 3):S3/122-31. (Level III)
35. Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol 2003;102:259-265 (Level III)
36. Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-132 (Level III)
37. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-177 (Meta-analysis)
38. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989;262:931-934 (Level III)
39. Broder S. From the National Institutes of Health. JAMA 1992;267:1892. (Level III)
40. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Forum Group Members; Bethesda 2001 Workshop. JAMA 2002;287: 2114-2119 (Level III)
41. Management of abnormal cervical cytology and histology. ACOG Practice Bulletin No. 99. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008; 112:1419-1444 (Level III)
42. Sherman ME, Tabbara SO, Scott DR, Kurman RJ, Glass AG, Manos MM, et al. "ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection. Mod Pathol 1999;12:335-342 (Level II-2)
43. Sherman ME, Solomon D, Schiffman M. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. ASCUS LSIL Triage Study Group. Am J Clin Pathol 2001;116:386-394 (Level II-2)
44. Veljovich DS, Stoler MH, Andersen WA, Covell JL, Rice LW. Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study. Am J Obstet Gynecol 1998;179:382-390 (Level III)
45. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. Am J Obstet Gynecol 2007;197:346-355 (Level III)
46. Davey DD, Austin RM, Birdsong G, Buck HW, Cox JT, Darragh TM, et al. ASCCP patient management guidelines: pap test specimen adequacy and quality indicators. J Low Genit Tract Dis 2002;6:195-199 (Level III)
47. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371 (Level II-2)
48. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neopla-sia. JAMA 2001;286:3106-3114 (Level II-2)
49. Wright JD, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, et al. Cervical dysplasia in adolescents. Obstet Gynecol 2005;106:115-120 (Level II-3)
50. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113(suppl):2855-2864 (Level II-3)
51. Evaluation and management of abnormal cervical cytology and histology in adolescents. ACOG Committee Opinion No. 436. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:1422-1425 (Level III)
52. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-498 (Meta-analysis)
53. Sexually transmitted diseases treatment guidelines, 2006. Centers for Disease Control and Prevention. MMWR Recomm Rep 2006 55(RR-11): 1-94.
54. 2006. Available at: http://www.cdc.gov/STD/Treatment/2006/rr5511.pdf. Retrieved July 20, 2009. (Level III)
55. Baldauf JJ, Dreyfus M, Ritter J, Cuenin C, Tissier I, Meyer P. Cytology and colposcopy after loop electrosur-gical excision: implications for follow-up. Obstet Gynecol 1998;92:124-130 (Level II-2)
56. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. Am J Obstet Gynecol 2007; 197:340-345 (Level III)
57. Flannelly G, Langhan H, Jandial L, Mana E, Campbell M, Kitchener H. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1997;104:718-722 (Level II-3) (Pubitemid 27278356)
58. Pettersson F, Malker B. Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a National Cancer Registry. Radiother Oncol 1989;16:115-120 (Level II-2)
59. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118: 2048-2055 (Level III)
60. Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med 2001;344:1603-1607 (Level III)
61. Agency for Health Care Policy and Research. Evaluation of cervical cytology. Evidence Report/Technology Assessment No. 5. AHCPR Publication No. 99-E010. Rockville (MD): AHCPR; 1999. (Level III)
62. Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501-1509 (Level III)
63. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J 1986;293:659-664 (Level II-3)
64. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000; 96:219-223 (Level II-3)
65. Eddy DM. The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data. Cancer 1987;60:1117-1122 (Level III)
66. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93. (Level II-3)
67. Miller MG, Sung HY, Sawaya GF, Kearney KA, Kinney W, Hiatt RA. Screening interval and risk of invasive squa-mous cell cervical cancer. Obstet Gynecol 2003;101:29-37. (Level II-2)
68. Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, et al. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006;107: 321-328 (Level III)
69. Sawaya GF, Sung HY, Kearney KA, Miller M, Kinney W, Hiatt RA, et al. Advancing age and cervical cancer screening and prognosis. J Am Geriatr Soc 2001;49:1499-1504 (Level II-3)
70. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968. (Level II-2)
71. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007;335:28. (Level I)
72. Eaker S, Adami HO, Sparen P. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med 2001;32:482-491 (Level II-2) (Pubitemid 32568518)
73. Mamoon H, Taylor R, Morrell S, Wain G, Moore H. Cervical screening: population-based comparisons between self-reported survey and registry-derived Pap test rates. Aust N Z J Public Health 2001;25:505-510 (Level II-2)
74. Sawyer JA, Earp JA, Fletcher RH, Daye FF, Wynn TM. Accuracy of women's self-report of their last Pap smear. Am J Public Health 1989;79:1036-1037 (Level II-2)
75. Boyce JG, Fruchter RG, Romanzi L, Sillman FH, Maiman M. The fallacy of the screening interval for cervical smears. Obstet Gynecol 1990;76:627-632 (Level II-2)
76. U.S. Census Bureau. U.S. interim projections by age, sex, race, and Hispanic origin: 2000-2050. Washington, DC: USCB; 2004. Available at: http://www.census.gov/population/ www/projections/usinterimproj. Retrieved July 21, 2009. (Level III)
77. Sawaya GF, Grady D, Kerlikowske K, Valleur JL, Barnabei VM, Bass K, et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med 2000;133:942-950 (Level II-2)
78. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. American Cancer Society. CA Cancer J Clin 2002; 52:342-362 (Level III)
79. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41. (Level III)
80. U.S. Preventive Services Task Force. Screening for cervical cancer. Systematic Evidence Review No. 25. Rockville (MD): Agency for Health Care Research and Quality; 2002. Available at http://www.ahrq.gov/downloads/pub/ prevent/ pdfser/cervcanser.pdf. Retrieved July 21, 2009. (Level III)
81. Stokes-Lampard H, Wilson S, Waddell C, Ryan A, Holder R, Kehoe S. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 2006;113:1354-1365 (Level III)
82. Kalogirou D, Antoniou G, Karakitsos P, Botsis D, Papadimitriou A, Giannikos L. Vaginal intraepithelial neo-plasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. Eur J Gynaecol Oncol 1997;18:188-191 (Level II-2)
83. Sillman FH, Fruchter RG, Chen YS, Camilien L, Sedlis A, McTigue E. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management. Am J Obstet Gynecol 1997;176:93-99 (Level II-2)
84. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605-1610 (Level II-2)
85. Wright TC Jr, Lorincz A, Ferris DG, Richart RM, Ferenczy A, Mielzynska I, et al. Reflex human papilloma-virus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998; 178:962-966 (Level II-2)
86. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol 2000;96:410-416 (Cost-effectiveness analysis)
87. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cyto-logic atypia. Obstet Gynecol 2000;95:821-827 (Level II-1)
88. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. ASCUS-LSIL Triage Study (ALTS) Group. Am J Obstet Gynecol 2003;188:1383-1392 (Level I)
89. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(suppl 3): S3/78-89. Level III
90. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-2390 (Cost-effectiveness analysis)
91. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101 (Level III)
92. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. Canadian Cervical Cancer Screening Trial Study Group. N Engl J Med 2007;357:1579-1588 (Level I)
93. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillo-mavirus testing alone with conventional cytology as the primary cervical cancer screening test. New Technologies for Cervical Cancer Screening Working Group. J Natl Cancer Inst 2008;100:492-501. (Level I)
94. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Joint European Cohort Study. BMJ 2008;337:a1754. (Level II-3)
95. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papil-lomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52. (Level II-2)
96. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer [published erratum appears in N Engl J Med 2008;359:1637]. N Engl J Med 2007;357:1589-1597 (Level I)
97. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772 (Level I)